Drugs / BCD-100
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03050047 | Aug 2016 → Jul 2017 | lung cancer, melanoma, renal cell carcinoma | Biocad | Unknown | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03913923 | Jul 2019 → Jul 2023 | metastatic melanoma | Biocad | Unknown | No outcome recorded |
| Phase 2 | NCT03912402 | Dec 2018 → Jul 2020 | cervical cancer | Biocad | Unknown | No outcome recorded |
| Phase 2 | NCT03269565 | Aug 2017 → Aug 2018 | melanoma | Biocad | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03288870 | Sep 2017 → Aug 2020 | non-small cell lung carcinoma | Biocad | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03912415 | Oct 2019 → Dec 2024 | cervical cancer | Biocad | Unknown | No outcome recorded |
| Phase 3 | NCT03912389 | Jun 2019 → Dec 2023 | non-small cell lung carcinoma | Biocad | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCD-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03269565 ↗ |
| Action | Inhibit | “Anti-PD-1 monoclonal antibody” NCT03912389 ↗ |
| Modality | Monoclonal antibody | “Anti-PD1 monoclonal antibody” NCT03050047 ↗ |
| Route | Intravenous | “Monotherapy, BCD-100 1 mg/kg Q2W (IV infusion over 60 minutes; if a 60-minute infusion is tolerated well, all following doses can be administered over 30 minutes);” NCT03269565 ↗ |